Why Embecta Stock Plummeted Today

Source The Motley Fool

Key Points

  • Embecta's recent quarterly report arrived with disappointing results.

  • Sales and earnings for fiscal Q2 came in far weaker than anticipated.

  • Embecta's outlook appears weaker following its latest quarterly report.

  • These 10 stocks could mint the next wave of millionaires ›

Embecta (NASDAQ: EMBC) stock crashed Tuesday following the company's latest quarterly report. The medical-device specialist's share price ended the daily session down 57.8%.

Before the market opened this morning, Embecta published results for the second quarter of its 2026 fiscal year -- which ended March 31. The company's sales and earnings for the period came in significantly weaker than expected, and investors aren't feeling optimistic about the near-term future.

Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue »

A person looking at chart lines going down.

Image source: Getty Images.

Embecta posted big misses in fiscal Q2

With its fiscal Q2 report, Embecta announced non-GAAP (adjusted) earnings per share of $0.27 on sales of $221.8 million. Meanwhile, the average analyst estimate had called for the business to record an adjusted profit of $0.42 per share on sales of roughly $235.7 million. Embecat's sales unexpectedly declined 14.4% year over year in fiscal Q2, and margins were significantly softer tahn anticipated. The company recorded an adjsuted earnings before interest, taxes, depreciation, and amortization (EBITDA) margin of 29.1% in the quarter -- down from a margin of 37.5% in last year's quarter.

What's on deck for Embecta?

With its fiscal Q2 report, Embecta lowered its full-year sales guidance to between $1.015 billion and $1.035 -- down from previous guidance for sales between $1.071 billion and $1.093 billion. The downward sales revision doesn't look massive, but it does raise questions about the company's near-term growth outlook. Meanwhile, the company's adjusted operating margin is now expected to be between 22.25% and 23.25% -- representing a substantial reduction from the previous guidance for a margin between 29% and 30% in the period.

The company expects to close its acquisition of Owen Mumford and for the purchase to have a dilutive impact on earnings of roughly $0.15 per share. While acquisition-related expenses will present an earnings headwind, the company's move to lower guidance on adjusted earnings per share from between $2.80 and $3 to between $1.55 per share and $1.75 per share raises some big questions for investors.

Where to invest $1,000 right now

When our analyst team has a stock tip, it can pay to listen. After all, Stock Advisor’s total average return is 963%* — a market-crushing outperformance compared to 201% for the S&P 500.

They just revealed what they believe are the 10 best stocks for investors to buy right now, available when you join Stock Advisor.

See the stocks »

*Stock Advisor returns as of May 5, 2026.

Keith Noonan has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Disclaimer: For information purposes only. Past performance is not indicative of future results.
placeholder
Bitcoin CME gaps at $35,000, $27,000 and $21,000, which one gets filled first?Prioritize filling the $27,000 gap and even try higher.
Author  FXStreet
Aug 22, 2023
Prioritize filling the $27,000 gap and even try higher.
placeholder
Elon Musk’s xAI and Neuralink Launch New Funding Rounds​Billionaire Elon Musk recently raised funds for his two high-profile tech companies, xAI and Neuralink.
Author  Insights
Jun 03, 2025
​Billionaire Elon Musk recently raised funds for his two high-profile tech companies, xAI and Neuralink.
placeholder
ECB Policy Outlook for 2026: What It Could Mean for the Euro’s Next MoveWith the ECB likely holding rates steady at 2.15% and the Fed potentially extending cuts into 2026, EUR/USD may test 1.20 if Eurozone growth proves resilient, but weaker growth and an ECB pivot could pull the pair back toward 1.13 and potentially 1.10.
Author  Mitrade
Dec 26, 2025
With the ECB likely holding rates steady at 2.15% and the Fed potentially extending cuts into 2026, EUR/USD may test 1.20 if Eurozone growth proves resilient, but weaker growth and an ECB pivot could pull the pair back toward 1.13 and potentially 1.10.
placeholder
My Top 5 Stock Market Predictions for 2026Five 2026 market predictions written in a native, news-style voice: AI’s winners and losers, broader sector leadership, dividend demand, valuation cooling as the Shiller CAPE sits at 39 (Dec. 31, 2025), and quantum-computing bursts—while keeping all original facts and numbers unchanged.
Author  Mitrade
Jan 06, Tue
Five 2026 market predictions written in a native, news-style voice: AI’s winners and losers, broader sector leadership, dividend demand, valuation cooling as the Shiller CAPE sits at 39 (Dec. 31, 2025), and quantum-computing bursts—while keeping all original facts and numbers unchanged.
placeholder
WTI Oil pulls back as Hormuz supply worries ease, Iran-US tensions keep volatility highWest Texas Intermediate (WTI) trades around $101.10 on Tuesday, down 1.26% at the time of writing, after posting strong gains the previous day amid escalating geopolitical tensions in the Middle East.
Author  FXStreet
15 hours ago
West Texas Intermediate (WTI) trades around $101.10 on Tuesday, down 1.26% at the time of writing, after posting strong gains the previous day amid escalating geopolitical tensions in the Middle East.
goTop
quote